(S (NP-SBJ (JJ Anti-CD2) (NN receptor) (NNS antibodies)) (VP (VBP activate) (NP (NP (DT the) (NN HIV) (JJ long) (JJ terminal) (NN repeat)) (PP (IN in) (NP (NN T) (NNS lymphocytes))))) (. .))
(S (NP-SBJ (DT The) (NN CD2) (NN T) (NN lymphocyte) (NN glycoprotein) (NN surface) (NN molecule)) (VP (VBZ mediates) (NP (NP-COOD (CC both) (NP (NN cell) (TO to) (NN cell) (NN adhesion)) (CC and) (NP (NN T) (NN cell) (NN activation))) (, ,) (NP (NP (CD two) (NNS processes)) (SBAR (WHNP-20 (WDT that)) (S (NP-SBJ-21 (-NONE- *T*-20)) (VP (VBP are) (VP (VBN involved) (NP (-NONE- *-21)) (PP (IN in) (NP (NP (DT the) (NN spread)) (PP (IN of) (NP (NN HIV) (NN infection)))))))))))) (. .))
(S (NP-SBJ-22 (NP (NN Treatment)) (PP (IN of) (NP (ADJP (RB chronically) (JJ HIV-infected)) (NN PBMC))) (PP (IN with) (NP (JJ anti-CD2) (NN mAb)))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (NP-SBJ (-NONE- *-22)) (VP (TO to) (VP (VB induce) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (JJ infectious) (NN virus)) (PP (IN from) (NP (DT these) (NNS cultures)))))))))))) (. .))
(S (PP (IN In) (NP (DT this) (NN study))) (NP-SBJ (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NNS mechanisms)) (SBAR (WHADVP-23 (WRB whereby)) (S (NP-SBJ (JJ anti-CD2) (NNS antibodies)) (VP (VBP stimulate) (NP (JJ viral) (NN production)) (PP (-NONE- *T*-23))))))) (. .))
(S (NP-SBJ (PRP We)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (NP (NN treatment)) (PP (IN of) (NP (ADJP (RB transiently) (VBN transfected)) (NN T) (NNS lymphocytes))) (PP (IN with) (NP (JJ anti-CD2) (NNS antibodies)))) (VP (VBZ results) (PP (IN in) (NP (NP (NN activation)) (PP (IN of) (NP (DT the) (NN HIV) (JJ long) (JJ terminal) (NN repeat))))))))) (. .))
(S (ADVP (RB Furthermore)) (, ,) (NP-SBJ-COOD (NP (NP (NN CAT) (NNS assays)) (VP (VBG using) (NP (VBN mutated) (NN HIV) (ADJP (JJ long) (JJ terminal) (NN repeat-CAT)) (NNS constructs)))) (CC and) (NP (NN gel) (NN shift) (NNS assays))) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (DT this) (NN activation)) (VP (VBZ is) (ADJP-PRD (JJ dependent) (PP (IN on) (NP (DT the) (NN NF-kappa) (NN B) (NN enhancer)))))))) (. .))
(S (NP-SBJ (DT These) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NP (NN interaction)) (PP (IN of) (NP (NN CD2))) (PP (IN with) (NP (NP (PRP$ its) (JJ natural) (NN ligand)) (, ,) (NP (NN LFA-3)) (, ,)))) (VP (MD may) (VP (VB play) (NP (DT a) (NN role)) (PP (IN in) (NP (NP (NN regulation)) (PP (IN of) (NP (NN HIV) (NN expression)))))))))) (. .))
